Posters

Intravitreal triamcinolone in treatment of pseudophakic macular edema (Irvine-Gass syndrome)

Poster Details

First Author: I.Tzamichas GREECE

Co Author(s):    T. Paschaloglou   P. Kalouda   C. Keskini   E. Zopounidou   G. Sakkias                 

Abstract Details



Purpose:

To investigate the efficacy and safety of intravitreal triamcinolone injection in cases of refractory pseudophakic cystoid macular edema (CME).

Setting:

Ophthalmology Department, Hippokrateio General Hospital, Thessaloniki, GREECE.

Methods:

Retrospective case series of patients with pseudophakic CME resistant to conventional medical therapy (mean duration 2 months). All patients were injected with 4 mg (0.1 ml) of triamcinolone acetonide.The patients underwent a complete ophthalmic examination 3 and 6 months after initial visit, including measurement of best corrected visual acuity (BCVA), intraocular pressure (IOP), central macular thickness (CMT) using spectral-domain optical coherence tomography (SD-OCT). Fundus fluoroscein angiography (FFA) was performed at baseline.

Results:

Ten eyes (10 patients) were enrolled into this study. Posterior capsule rupture was present in 2 eyes, mild epimacular membrane in 4 eyes, mild diabetic retinopathy without centre involved macular edema in 2 eyes and partial iris capture in 2 eyes. After a 6 month follow-up mean BCVA increased from 0.64 LogMAR to 0.18 LogMAR (4 lines of vision gained). Baseline mean CMT decreased from 437 μm to 287 μm. Mean IOP values were 14.4 mmHg (prior to the injection) and 15.5 mmHg (after 6 months). No ocular side effects were recorded.

Conclusions:

Intravitreal triamcinolone acetonide injection is safe and effective in treating long-lasting Irvine-Gass syndrome cases.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy